Form 4: Haemonetics EVP, Chief Financial Officer James D'Arecca Reports Stock and Option Awards

James D'Arecca, EVP and CFO of Haemonetics, reports the acquisition of restricted stock units and stock options.

Summary

• James D'Arecca, the EVP and Chief Financial Officer of Haemonetics Corp, filed a Form 4 on May 20, 2025, reporting transactions made on May 16, 2025.
• The filing indicates the acquisition of 7,111 shares of common stock in the form of restricted stock units (RSUs) and 15,396 non-qualified stock options.
• The RSUs vest in three equal annual installments starting on the first anniversary of the grant date, and each RSU represents a contingent right to receive one share of Haemonetics common stock when vested.
• The stock options vest in annual increments of 25% beginning on the first anniversary of the grant date and have an exercise price of $70.31.
• Following these transactions, D'Arecca beneficially owns 21,935 shares of common stock and 15,396 derivative securities.

Sentiment

Score: 7

Explanation: The sentiment is neutral to slightly positive. It reflects standard executive compensation practices, which are generally viewed favorably as they align management's interests with shareholders.

Positives

• The granting of RSUs and stock options to the CFO aligns his interests with those of the shareholders.
• The vesting schedules for both the RSUs and stock options encourage long-term commitment from the executive.

Industry Context

Form 4 filings are a routine part of executive compensation and are common in publicly traded companies. They provide transparency into the transactions of company insiders.

Comparison to Industry Standards

• Executive compensation packages, including stock options and RSUs, are standard practice in publicly traded companies like Haemonetics to incentivize and retain key personnel.
• The vesting schedules described are typical for such awards, aligning executive interests with long-term shareholder value.
• Comparable companies such as Baxter International and Medtronic also utilize similar equity-based compensation strategies.

Stakeholder Impact

• The granting of RSUs and stock options can positively impact shareholders by aligning executive interests with long-term company performance.
• Employees may view the executive compensation package as a sign of the company's commitment to its leadership.

Key Dates

Keywords

Form 4, Haemonetics, Executive Compensation, Stock Options, Restricted Stock Units, Beneficial Ownership, Insider Trading